Selective serotonin reuptake inhibitors

Future treatment of vascular disease? New evidence linking platelets, depression, and coronary events

Alex I. Malinin, Dan Atar, Victor L. Serebruany

Research output: Contribution to journalArticle

Abstract

There is substantial clinical evidence today that the incidence of depression and mortality after acute coronary syndromes are strongly related. The main effectors of coronary thrombosis are platelets, and hence, alterations of platelets and their functional characteristics may represent a conceptual bridge between these events. Selective serotonin reuptake inhibitors (SSRI), such as sertraline, have become an established therapy in patients with depression. These drugs provide not only a safe blockade of serotonin reuptake in the brain, but also in platelets, thus potentially protecting them from activation. However, the ability of sertraline therapy to deliver clinically meaningful antiplatelet effects and reduce thrombotic events, particularly acute coronary syndromes, is yet unexplored. Nevertheless, the platelet-related properties of SSRI may strongly affect the incidence of complications in patients with ischemic heart disease. Moreover, even marginal clinical benefits, together with recently reported severe bleeding events in some patients receiving oral platelet glycoprotein IIb/IIIa therapy, may potentially advance sertraline as a safe and efficient adjunct to the current therapeutic approach to the acute coronary syndrome. Further well-designed and carefully conducted clinical trials should elucidate the potential benefits of SSRI in an expanding array of clinical conditions, including myocardial infarction and unstable angina, with a prospect of SSRI to become suitable drugs, for example, in the convalescent phase of an ischemic event.

Original languageEnglish (US)
Pages (from-to)332-340
Number of pages9
JournalHeartDrug
Volume1
Issue number6
DOIs
StatePublished - 2001

Fingerprint

Serotonin Uptake Inhibitors
Vascular Diseases
Sertraline
Blood Platelets
Acute Coronary Syndrome
Integrin beta3
Coronary Thrombosis
Platelet Glycoprotein GPIIb-IIIa Complex
Incidence
Unstable Angina
Therapeutics
Pharmaceutical Preparations
Myocardial Ischemia
Serotonin
Myocardial Infarction
Clinical Trials
Hemorrhage
Mortality
Brain

Keywords

  • Depression
  • Myocardial infarction
  • Platelets
  • Sertraline

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Selective serotonin reuptake inhibitors : Future treatment of vascular disease? New evidence linking platelets, depression, and coronary events. / Malinin, Alex I.; Atar, Dan; Serebruany, Victor L.

In: HeartDrug, Vol. 1, No. 6, 2001, p. 332-340.

Research output: Contribution to journalArticle

@article{9486b7b73b5a4f63b23d3385ff5788d4,
title = "Selective serotonin reuptake inhibitors: Future treatment of vascular disease? New evidence linking platelets, depression, and coronary events",
abstract = "There is substantial clinical evidence today that the incidence of depression and mortality after acute coronary syndromes are strongly related. The main effectors of coronary thrombosis are platelets, and hence, alterations of platelets and their functional characteristics may represent a conceptual bridge between these events. Selective serotonin reuptake inhibitors (SSRI), such as sertraline, have become an established therapy in patients with depression. These drugs provide not only a safe blockade of serotonin reuptake in the brain, but also in platelets, thus potentially protecting them from activation. However, the ability of sertraline therapy to deliver clinically meaningful antiplatelet effects and reduce thrombotic events, particularly acute coronary syndromes, is yet unexplored. Nevertheless, the platelet-related properties of SSRI may strongly affect the incidence of complications in patients with ischemic heart disease. Moreover, even marginal clinical benefits, together with recently reported severe bleeding events in some patients receiving oral platelet glycoprotein IIb/IIIa therapy, may potentially advance sertraline as a safe and efficient adjunct to the current therapeutic approach to the acute coronary syndrome. Further well-designed and carefully conducted clinical trials should elucidate the potential benefits of SSRI in an expanding array of clinical conditions, including myocardial infarction and unstable angina, with a prospect of SSRI to become suitable drugs, for example, in the convalescent phase of an ischemic event.",
keywords = "Depression, Myocardial infarction, Platelets, Sertraline",
author = "Malinin, {Alex I.} and Dan Atar and Serebruany, {Victor L.}",
year = "2001",
doi = "10.1159/000048983",
language = "English (US)",
volume = "1",
pages = "332--340",
journal = "HeartDrug",
issn = "1422-9528",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Selective serotonin reuptake inhibitors

T2 - Future treatment of vascular disease? New evidence linking platelets, depression, and coronary events

AU - Malinin, Alex I.

AU - Atar, Dan

AU - Serebruany, Victor L.

PY - 2001

Y1 - 2001

N2 - There is substantial clinical evidence today that the incidence of depression and mortality after acute coronary syndromes are strongly related. The main effectors of coronary thrombosis are platelets, and hence, alterations of platelets and their functional characteristics may represent a conceptual bridge between these events. Selective serotonin reuptake inhibitors (SSRI), such as sertraline, have become an established therapy in patients with depression. These drugs provide not only a safe blockade of serotonin reuptake in the brain, but also in platelets, thus potentially protecting them from activation. However, the ability of sertraline therapy to deliver clinically meaningful antiplatelet effects and reduce thrombotic events, particularly acute coronary syndromes, is yet unexplored. Nevertheless, the platelet-related properties of SSRI may strongly affect the incidence of complications in patients with ischemic heart disease. Moreover, even marginal clinical benefits, together with recently reported severe bleeding events in some patients receiving oral platelet glycoprotein IIb/IIIa therapy, may potentially advance sertraline as a safe and efficient adjunct to the current therapeutic approach to the acute coronary syndrome. Further well-designed and carefully conducted clinical trials should elucidate the potential benefits of SSRI in an expanding array of clinical conditions, including myocardial infarction and unstable angina, with a prospect of SSRI to become suitable drugs, for example, in the convalescent phase of an ischemic event.

AB - There is substantial clinical evidence today that the incidence of depression and mortality after acute coronary syndromes are strongly related. The main effectors of coronary thrombosis are platelets, and hence, alterations of platelets and their functional characteristics may represent a conceptual bridge between these events. Selective serotonin reuptake inhibitors (SSRI), such as sertraline, have become an established therapy in patients with depression. These drugs provide not only a safe blockade of serotonin reuptake in the brain, but also in platelets, thus potentially protecting them from activation. However, the ability of sertraline therapy to deliver clinically meaningful antiplatelet effects and reduce thrombotic events, particularly acute coronary syndromes, is yet unexplored. Nevertheless, the platelet-related properties of SSRI may strongly affect the incidence of complications in patients with ischemic heart disease. Moreover, even marginal clinical benefits, together with recently reported severe bleeding events in some patients receiving oral platelet glycoprotein IIb/IIIa therapy, may potentially advance sertraline as a safe and efficient adjunct to the current therapeutic approach to the acute coronary syndrome. Further well-designed and carefully conducted clinical trials should elucidate the potential benefits of SSRI in an expanding array of clinical conditions, including myocardial infarction and unstable angina, with a prospect of SSRI to become suitable drugs, for example, in the convalescent phase of an ischemic event.

KW - Depression

KW - Myocardial infarction

KW - Platelets

KW - Sertraline

UR - http://www.scopus.com/inward/record.url?scp=0035714922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035714922&partnerID=8YFLogxK

U2 - 10.1159/000048983

DO - 10.1159/000048983

M3 - Article

VL - 1

SP - 332

EP - 340

JO - HeartDrug

JF - HeartDrug

SN - 1422-9528

IS - 6

ER -